Reports Q1 revenue $28.2M, consensus $30.34M. With our recent 510(k) clearance for TabloCart with Prefiltration, 12th consecutive quarter of gross margin expansion and strong sales pipeline growth during the quarter, we are well positioned to capitalize on the $11 billion U.S. dialysis market opportunity,” said Leslie Trigg, Chair and Chief Executive Officer. “Tablo’s uniquely compelling value proposition continues to resonate with acute- and home-care providers, with significant new customer wins in both settings during the quarter.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical says FDA grants 510(k) clearance of TabloCart with prefiltration
- Stifel says Outset TabloCart with Prefiltration approval earlier than expected
- FDA posts 510(k) approval of Outset Medical’s TabloCart
- Outset Medical U.S. Renal Care in deal to expand U.S. home dialysis
- Outset Medical initiated with a Buy at BTIG
Questions or Comments about the article? Write to editor@tipranks.com